Tonix Pharmaceuticals (NASDAQ:TNXP) Earns Hold Rating from Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a note issued to investors on Friday. The brokerage set a “hold” rating on the stock.

Tonix Pharmaceuticals Price Performance

Shares of NASDAQ:TNXP opened at $0.24 on Friday. Tonix Pharmaceuticals has a fifty-two week low of $0.12 and a fifty-two week high of $12.48. The company’s 50-day moving average is $0.26 and its 200 day moving average is $0.31. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The company has a market capitalization of $43.92 million, a P/E ratio of 0.00 and a beta of 2.02.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. On average, equities research analysts forecast that Tonix Pharmaceuticals will post -17.63 earnings per share for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.